1. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
- Author
-
Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, and Kim RB
- Subjects
- Adolescent, Adult, Area Under Curve, Biotransformation drug effects, Clopidogrel, Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP3A drug effects, Enzyme Inhibitors pharmacokinetics, Enzyme Inhibitors pharmacology, Humans, Midazolam pharmacokinetics, Midazolam pharmacology, Middle Aged, Platelet Aggregation drug effects, Platelet Aggregation genetics, Platelet Aggregation Inhibitors pharmacokinetics, Ticlopidine pharmacokinetics, Ticlopidine pharmacology, Young Adult, Aryl Hydrocarbon Hydroxylases genetics, Aryldialkylphosphatase genetics, Platelet Aggregation Inhibitors pharmacology, Polymorphism, Genetic genetics, Ticlopidine analogs & derivatives
- Abstract
Aims: It is thought that clopidogrel bioactivation and antiplatelet response are related to cytochrome P450 2C19 (CYP2C19). However, a recent study challenged this notion by proposing CYP2C19 as wholly irrelevant, while identifying paraoxonase-1 (PON1) and its Q192R polymorphism as the major driver of clopidogrel bioactivation and efficacy. The aim of this study was to systematically elucidate the mechanism and relative contribution of PON1 in comparison to CYP2C19 to clopidogrel bioactivation and antiplatelet response., Methods and Results: First, the influence of CYP2C19 and PON1 polymorphisms and plasma paraoxonase activity on clopidogrel active metabolite (H4) levels and antiplatelet response was assessed in a cohort of healthy subjects (n = 21) after administration of a single 75 mg dose of clopidogrel. There was a remarkably good correlation between H4 AUC (0-8 h) and antiplatelet response (r2 = 0.78). Furthermore, CYP2C19 but not PON1 genotype was predictive of H4 levels and antiplatelet response. There was no correlation between plasma paraoxonase activity and H4 levels. Secondly, metabolic profiling of clopidogrel in vitro confirmed the role of CYP2C19 in bioactivating clopidogrel to H4. However, heterologous expression of PON1 in cell-based systems revealed that PON1 cannot generate H4, but mediates the formation of another thiol metabolite, termed Endo. Importantly, Endo plasma levels in humans are nearly 20-fold lower than H4 and was not associated with any antiplatelet response., Conclusion: Our results demonstrate that PON1 does not mediate clopidogrel active metabolite formation or antiplatelet action, while CYP2C19 activity and genotype remains a predictor of clopidogrel pharmacokinetics and antiplatelet response.
- Published
- 2012
- Full Text
- View/download PDF